Navigating the GSK-3β inhibitors as versatile multi-target drug ligands in Alzheimer’s disease intervention – A comprehensive review
Alzheimer’s disease (AD) remains a significant global health challenge, necessitating the exploration of novel therapeutic strategies. AD is a neurodegenerative disease characterized by the formation of amyloid-β (Aβ) plaques and neurofibrillary tangles composed of tau protein. It is stated to be a...
Main Authors: | Nachiket Jitendra Joshi, Alavala Raja Sekhar Reddy |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-01-01
|
Series: | Results in Chemistry |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211715624001966 |
Similar Items
-
Multitargeted Virtual Screening and Molecular Simulation of Natural Product-like Compounds against GSK3β, NMDA-Receptor, and BACE-1 for the Management of Alzheimer’s Disease
by: Danish Iqbal, et al.
Published: (2023-04-01) -
The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
by: Ulf Neumann, et al.
Published: (2018-11-01) -
A Unique GSK-3β inhibitor B10 Has a Direct Effect on Aβ, Targets Tau and Metal Dyshomeostasis, and Promotes Neuronal Neurite Outgrowth
by: Xiao-Long Shi, et al.
Published: (2020-03-01) -
Development of p-Tau Differentiated Cell Model of Alzheimer’s Disease to Screen Novel Acetylcholinesterase Inhibitors
by: Giuseppe Uras, et al.
Published: (2022-11-01) -
The efficacy and safety of anti-Aβ agents for delaying cognitive decline in Alzheimer’s disease: a meta-analysis
by: Jiaxuan Li, et al.
Published: (2023-11-01)